Accession Number: | 0001104659-20-081337 |
Date: | 2020-07-01 |
Issuer: | ACCELERON PHARMA INC (XLRN) |
Original Submission Date: |
CELGENE CORP /DE/
86 MORRIS AVENUE
SUMMIT, NJ 07901
BRISTOL MYERS SQUIBB CO
430 E. 29TH STREET
14 FLOOR
NEW YORK, NY 10016
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-07-01 | P | 108,108 | a | $92.50 | 6,971,772 f2 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | this statement is being filed jointly by celgene corporation and bristol-myers squibb company. |
f2 | these shares are owned directly by celgene corporation, which is a wholly owned subsidiary of bristol-myers squibb company. bristol-myers squibb company is an indirect beneficial owner of the reported securities. |